Literature DB >> 26642365

Serum amyloid A impairs the antiinflammatory properties of HDL.

Chang Yeop Han, Chongren Tang, Myriam E Guevara, Hao Wei, Tomasz Wietecha, Baohai Shao, Savitha Subramanian, Mohamed Omer, Shari Wang, Kevin D O'Brien, Santica M Marcovina, Thomas N Wight, Tomas Vaisar, Maria C de Beer, Frederick C de Beer, William R Osborne, Keith B Elkon, Alan Chait.   

Abstract

HDL from healthy humans and lean mice inhibits palmitate-induced adipocyte inflammation; however, the effect of the inflammatory state on the functional properties of HDL on adipocytes is unknown. Here, we found that HDL from mice injected with AgNO3 fails to inhibit palmitate-induced inflammation and reduces cholesterol efflux from 3T3-L1 adipocytes. Moreover, HDL isolated from obese mice with moderate inflammation and humans with systemic lupus erythematosus had similar effects. Since serum amyloid A (SAA) concentrations in HDL increase with inflammation, we investigated whether elevated SAA is a causal factor in HDL dysfunction. HDL from AgNO3-injected mice lacking Saa1.1 and Saa2.1 exhibited a partial restoration of antiinflammatory and cholesterol efflux properties in adipocytes. Conversely, incorporation of SAA into HDL preparations reduced antiinflammatory properties but not to the same extent as HDL from AgNO3-injected mice. SAA-enriched HDL colocalized with cell surface-associated extracellular matrix (ECM) of adipocytes, suggesting impaired access to the plasma membrane. Enzymatic digestion of proteoglycans in the ECM restored the ability of SAA-containing HDL to inhibit palmitate-induced inflammation and cholesterol efflux. Collectively, these findings indicate that inflammation results in a loss of the antiinflammatory properties of HDL on adipocytes, which appears to partially result from the SAA component of HDL binding to cell-surface proteoglycans, thereby preventing access of HDL to the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26642365      PMCID: PMC4701569          DOI: 10.1172/JCI83475

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  85 in total

1.  Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins.

Authors:  S T Kunitake; M R Jarvis; R L Hamilton; J P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

2.  Insulin resistance and metabolic syndrome: mechanisms and consequences.

Authors:  Ann Marie Schmidt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-08       Impact factor: 8.311

3.  SAA does not induce cytokine production in physiological conditions.

Authors:  Myung-Hee Kim; Maria C de Beer; Joanne M Wroblewski; Nancy R Webb; Frederick C de Beer
Journal:  Cytokine       Date:  2012-11-17       Impact factor: 3.861

Review 4.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

Authors:  Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet
Journal:  Circulation       Date:  2012-04-17       Impact factor: 29.690

5.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans.

Authors:  Tsuyoshi Chiba; Mary Y Chang; Shari Wang; Thomas N Wight; Timothy S McMillen; John F Oram; Tomas Vaisar; Jay W Heinecke; Frederick C De Beer; Maria C De Beer; Alan Chait
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-07       Impact factor: 8.311

7.  High-density lipoprotein reduces the human monocyte inflammatory response.

Authors:  Andrew J Murphy; Kevin J Woollard; Anh Hoang; Nigora Mukhamedova; Roslynn A Stirzaker; Sally P A McCormick; Alan T Remaley; Dmitri Sviridov; Jaye Chin-Dusting
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

8.  Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice.

Authors:  Maria C De Beer; Joanne M Wroblewski; Victoria P Noffsinger; Debra L Rateri; Deborah A Howatt; Anju Balakrishnan; Ailing Ji; Preetha Shridas; Joel C Thompson; Deneys R van der Westhuyzen; Lisa R Tannock; Alan Daugherty; Nancy R Webb; Frederick C De Beer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-11-21       Impact factor: 8.311

9.  Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids.

Authors:  Joo Y Lee; Anthony Plakidas; Won H Lee; Anne Heikkinen; Prithiva Chanmugam; George Bray; Daniel H Hwang
Journal:  J Lipid Res       Date:  2002-12-01       Impact factor: 5.922

10.  Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention?

Authors:  Fredric J Pashkow
Journal:  Int J Inflam       Date:  2011-08-11
View more
  46 in total

Review 1.  Role of serum amyloid A in atherosclerosis.

Authors:  Preetha Shridas; Lisa R Tannock
Journal:  Curr Opin Lipidol       Date:  2019-08       Impact factor: 4.776

2.  Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks.

Authors:  Nicholas M Frame; Olga Gursky
Journal:  FEBS Lett       Date:  2016-03-06       Impact factor: 4.124

3.  Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA.

Authors:  Shobini Jayaraman; Christian Haupt; Olga Gursky
Journal:  J Lipid Res       Date:  2016-10-15       Impact factor: 5.922

4.  Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.

Authors:  Bradley K Wacker; Nagadhara Dronadula; Lianxiang Bi; Alexis Stamatikos; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-09       Impact factor: 8.311

Review 5.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

6.  Glycation of HDL blunts its anti-inflammatory and cholesterol efflux capacities in vitro, but has no effect in poorly controlled type 1 diabetes subjects.

Authors:  Diego Gomes Kjerulf; Shari Wang; Mohamed Omer; Asha Pathak; Savitha Subramanian; Chang Yeop Han; Chongren Tang; Laura J den Hartigh; Baohai Shao; Alan Chait
Journal:  J Diabetes Complications       Date:  2020-07-31       Impact factor: 2.852

Review 7.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

Review 8.  Inflammation, remodeling, and other factors affecting HDL cholesterol efflux.

Authors:  Graziella E Ronsein; Tomáš Vaisar
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

Review 9.  Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?

Authors:  Alain Menzel; Hanen Samouda; Francois Dohet; Suva Loap; Mohammed S Ellulu; Torsten Bohn
Journal:  Antioxidants (Basel)       Date:  2021-03-09

10.  ABCA1 Overexpression in Endothelial Cells In Vitro Enhances ApoAI-Mediated Cholesterol Efflux and Decreases Inflammation.

Authors:  Alexis Stamatikos; Nagadhara Dronadula; Philip Ng; Donna Palmer; Ethan Knight; Bradley K Wacker; Chongren Tang; Francis Kim; David A Dichek
Journal:  Hum Gene Ther       Date:  2018-10-02       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.